- $7.35bn
- $6.72bn
- $36.13m
Brief: Merus N.V. Announces Proposed Public Offering Of Common Shares
U.S. STOCKS ON THE MOVE-Sarepta, Moderna, Merus
Merus falls on investor concerns over cancer therapy combo trial results
U.S. STOCKS ON THE MOVE-Gold miners, Dell, Nutanix
Cancer biotechs jump on data ahead of industry meet
U.S. STOCKS ON THE MOVE-XPO, Howmet Aerospace, Martin Midstream
Merus climbs after positive interim data for cancer therapy combo
Brief: Merus Announces Publication Of An Abstract On Petosemtamab With Pembrolizumab As 1L Treatment Of R/M HNSCC
Brief: Petosemtamab Granted Breakthrough Therapy Designation By The U.S. FDA
Brief: Merus Q1 Net Income USD -34.456 Million
Merus NV expected to post a loss of 81 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
U.S. STOCKS ON THE MOVE-Couchbase, Foot Locker, Nordstrom
Merus rises on Gilead collaboration to discover anti-body based therapies
Brief: Gilead, Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers
Merus NV reports results for the quarter ended in December - Earnings Summary
Merus NV expected to post a loss of 74 cents a share - Earnings Preview
Merus NV reports results for the quarter ended in September - Earnings Summary
Brief: Merus Q3 Net Income USD -23.012 Million